(:PRVB)

Mar 30, 2023 11:55 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMED, PRVB, INFI
NEW YORK, March 30, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Mar 29, 2023 02:58 pm ET
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Provention will receive only $25.00 in cash for each share of Provention that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Mar 29, 2023 09:00 am ET
SHAREHOLDER ALERT: Morris Kandinov Investigating PRVB, MAXR, DNA, and FOX; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating Provention Bio, Inc., Maxar Technologies Inc., Ginkgo Bioworks Holdings, Inc., and Fox Corporation. If you are a current owner of shares, contact [email protected] or call (619) 780-3993 to speak with...
Mar 23, 2023 10:08 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball Inter
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Mar 21, 2023 12:22 pm ET
Moore Kuehn Encourages RADI, PRVB, CVT, and UNVR Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Mar 19, 2023 10:16 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, ADAP, PRVB, XM
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ: SGEN)’s sale to...
Mar 18, 2023 08:11 pm ET
Lifshitz Law PLLC Announces Investigations of SGEN, PRVB, KBAL, and ADAP
Seagen Inc. (NASDAQ: SGEN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SGEN to Pfizer Inc. for $229.00 per share in cash. If you are a SGEN investor, and would like...
Mar 17, 2023 05:47 pm ET
(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Provention Bio Inc. (Nasdaq - PRVB) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi...
Mar 15, 2023 04:49 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, XM, PRVB, SGEN
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
Mar 14, 2023 10:28 am ET
Moore Kuehn Encourages XM, OSH, SGEN, and PRVB Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek...
Mar 14, 2023 08:43 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates PRVB, SGEN, XM
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Provention Bio, Inc. (NASDAQ: PRVB)’s...
Mar 14, 2023 03:32 am ET
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Provention Bio, Inc. - PRVB
NEW YORK, March 14, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Provention Bio, Inc. (NASDAQ: PRVB), relating to its proposed sale to Sanofi. Under the terms of the agreement PRVB shareholders are expected to receive $25.00 in cash per share they own. Click here for more information: https://www.mont
Mar 13, 2023 07:24 pm ET
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Provention will receive only $25.00 in cash for each share of Provention that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Mar 13, 2023 01:58 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball Internationa
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Mar 13, 2023 12:41 pm ET
Shareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with Sanofi
MILWAUKEE, March 13, 2023 /PRNewswire/ -- Ademi LLP is investigating Provention Bio (Nasdaq: PRVB) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. 
Mar 13, 2023 12:20 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates PRVB, SGEN, XM
NEW YORK, March 13, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Mar 13, 2023 09:17 am ET
PRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Provention Bio, Inc. (NASDAQ: PRVB) to Sanofi for $25.00 per share in cash is fair to Provention shareholders.
Mar 13, 2023 08:31 am ET
Thinking about buying stock in Provention Bio, Appreciate, ZIM Integrated Shipping, HIVE Blockchain, or AngloGold Ashanti?
NEW YORK, March 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRVB, SFR, ZIM, HIVE, and AU.
Mar 13, 2023 07:00 am ET
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
RED BANK, N.J., March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions. In addition, Provention will no longer hold its fourt
Feb 13, 2023 06:30 am ET
Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US
Companies collaborating to expand access to TZIELD™ (teplizumab-mzwv), the first approved disease-modifying therapy for type 1 diabetes
Feb 08, 2023 06:30 am ET
Provention Bio to Present at the SVB Securities Global Biopharma Conference
RED BANK, N.J., Feb. 8, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will participate in a fireside chat presentation at the SVB Securities Global Biopharma Conference on Wednesday, February 15th, 2023 at 11:20am EST.
Feb 03, 2023 03:01 pm ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., Feb. 3, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to 8 non-executive employees to purchase an aggregate of 124,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation committ
Feb 02, 2023 03:01 pm ET
Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®
RED BANK, N.J., Feb. 2, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the close of the $40 million second tranche under the previously announced term loan facility of up to $125 million with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized financing for companies in life sciences.
Jan 06, 2023 03:01 pm ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., January 6, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to 58 non-executive employees to purchase an aggregate of 763,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation com
Jan 05, 2023 03:01 pm ET
Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors
RED BANK, N.J., Jan. 5, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Rita Jain, M.D., to the Company's Board of Directors. Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, Inc., AbbVie, Abbott Laboratories, and G.D. Searle and Co. prior to the latter's merger with Pharmacia & Upjohn and subsequent acquisition by Pfizer.
Dec 02, 2022 03:01 pm ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., Dec. 2, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to three non-executive employees to purchase an aggregate of 84,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation comm
Nov 18, 2022 10:57 am ET
Thinking about buying stock in Provention Bio, DraftKings, Zendesk, Tencent Music Entertainment, or Yatra Online?
NEW YORK, Nov. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRVB, DKNG, ZEN, TME, and YTRA.
Nov 17, 2022 04:45 pm ET
TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stag
TZIELD is the first disease-modifying therapy in T1D, a life-threatening autoimmune diseaseIn a clinical trial, in Stage 2 T1D patients, TZIELD delayed the median onset of Stage 3 T1D by 25 months, or approximately 2 years, compared to placeboStage 3 T1D is associated with significant health risks, including diabetic ketoacidosis, which can be life threateningPatients who progress to Stage 3 T1D eventually require insulin injections for lifeInvestor Conference call at 8:00am ET tomorrowRED BANK, N.J., Nov. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopha
Nov 17, 2022 07:30 am ET
Thinking about buying stock in Macy's, Immunic, LexinFintech, Provention Bio, or Clearside Biomedical?
NEW YORK, Nov. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for M, IMUX, LX, PRVB, and CLSD.
Nov 04, 2022 04:05 pm ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., Nov. 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to five non-executive employees to purchase an aggregate of 80,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation commi
Nov 03, 2022 07:00 am ET
Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
Continues to Advance Preparations for Potential U.S. Commercial Launch of Teplizumab Ahead of November 17th FDA User Fee Goal Date
Oct 13, 2022 07:30 am ET
Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022
RED BANK, N.J., Oct. 13, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its third quarter 2022 financial results on Thursday, November 3, 2022, before the opening of the U.S. financial markets. The company will host a conference call at 8:00am E.T. to discuss its financial results and provide a company update.
Oct 07, 2022 04:01 pm ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., Oct. 7, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to a non-executive employee to purchase an aggregate of 10,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employee entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation committee
Oct 06, 2022 09:36 am ET
Thinking about buying stock in Heartbeam, Provention Bio, Pinterest, Quantum-Si, or Palantir Technologies?
NEW YORK, Oct. 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BEAT, PRVB, PINS, QSI, and PLTR.
Oct 06, 2022 07:00 am ET
Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
Provention receives $20 million nonrefundable payment granting Sanofi exclusive right of first negotiation to in-license teplizumab globally for T1D U.S. copromotion agreement leverages Sanofi's in-market infrastructure and established expertise in endocrinology to expand reach, increase awareness and drive T1D screeningSanofi to invest $35 million at a premium after a potential teplizumab FDA approval Investor Conference call at 8:30am ET TodayRED BANK, N.J. , Oct. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercept
Sep 19, 2022 07:30 am ET
Provention Bio Announces Senior Leadership Addition
RED BANK, N.J., Sept. 19, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has appointed Sarah O'Brien as Chief People Officer. Sarah brings more than 20 years of experience building strong employee culture and leading human resources within the biotech sector, and will report to CEO Ashleigh Palmer, effective immediately.
Sep 06, 2022 04:01 pm ET
Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
RED BANK, N.J., Sept. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12th at 7:00am EST.
Sep 02, 2022 04:01 pm ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., Sept. 2, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to two non-executive employees to purchase an aggregate of 38,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation commi
Aug 31, 2022 06:12 pm ET
Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital
RED BANK, N.J., Aug. 31, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has secured a term loan facility of up to $125 million with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized financing for companies in life sciences.
Aug 19, 2022 08:30 am ET
Thinking about buying stock in Axsome Therapeutics, Foot Locker, Mind Medicine, Digital Media Solutions, or Provention Bio?
NEW YORK, Aug. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, FL, MNMD, DMS, and PRVB.
Aug 04, 2022 07:00 am ET
Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
-Teplizumab Biologics License Application (BLA) user fee goal date extended to November 17, 2022-
Aug 02, 2022 04:05 pm ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., Aug. 2, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to nine non-executive employees to purchase an aggregate of 118,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation comm
Jul 28, 2022 07:30 am ET
Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
RED BANK, N.J., July 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a company update.
Jun 03, 2022 07:35 am ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to eight new employees to purchase an aggregate of 166,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation committee of the board of d
Jun 03, 2022 07:30 am ET
Provention Bio to Present at the Jefferies Global Healthcare Conference
RED BANK, N.J., June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a corporate presentation at the Jefferies Global Healthcare Conference on Wednesday, June 8th 2022 at 9:00 am EST in New York City.
Jun 03, 2022 07:00 am ET
Provention Bio Announces Update to Board of Directors
RED BANK, N.J., June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced Dr. Jeffrey Bluestone's decision to step down as a director on the Company's board of directors to focus on his other commitments, including his role as President and Chief Executive Officer of Sonoma Biotherapeutics. Dr. Bluestone will continue as Scientific Advisor to the Company.
May 12, 2022 07:30 am ET
Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year
RED BANK, N.J., May 12, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will host an investor event on Thursday, May 19, 2022 focused on the potential commercial launch of teplizumab in the second half of this year. The event is scheduled to take place from 1:00 p.m. to approximately 2:30 p.m. ET in a virtual format.
May 05, 2022 07:00 am ET
Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update
-Teplizumab Biologics License Application (BLA) resubmission accepted for review by FDA and user fee goal date set for August 17, 2022-
May 03, 2022 07:30 am ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., May 3, 2022 /PRNewswire/ --Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to four new employees to purchase an aggregate of 110,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation committee of the board of dire
Apr 28, 2022 07:30 am ET
Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022
RED BANK, N.J., April 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a company update.
Apr 04, 2022 04:05 pm ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., April 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to two new employees to purchase an aggregate of 195,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation committee of the board of di
Mar 28, 2022 07:30 am ET
Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
PRV-101 continued to be well tolerated and elicited durable high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers
Mar 04, 2022 03:05 pm ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., March 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to two new employees to purchase an aggregate of 55,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation committee of the board of dir
Mar 03, 2022 06:30 am ET
Provention Bio to Present at Two Upcoming Virtual Investor Conferences
RED BANK, N.J., March 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in two upcoming virtual investor conferences in March.
Feb 24, 2022 06:00 am ET
Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
RED BANK, N.J., Feb. 24, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.
Feb 22, 2022 06:30 am ET
Provention Bio Announces Biologics License Application (BLA) Resubmission for Teplizumab to Address Complete Response Letter (CRL)
RED BANK, N.J., Feb. 22, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced it has resubmitted the Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.
Feb 17, 2022 03:05 pm ET
Provention Bio to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
RED BANK, N.J., Feb. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a corporate update.
Feb 10, 2022 06:30 am ET
Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference
RED BANK, N.J., Feb. 10, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16th, 2022 at 10:00am EST.
Feb 04, 2022 03:05 pm ET
Provention Bio Announces the Grant of Inducement Award
RED BANK, N.J., Feb. 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options on February 1, 2022 to a new non-executive employee to purchase an aggregate of 30,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employee entering into employment with the Company pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's
Jan 28, 2022 07:36 am ET
Thinking about buying stock in NeoGenomics, Provention Bio, Exela Technologies, Braskem SA, or Rewalk Robotics?
NEW YORK, Jan. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEO, PRVB, XELA, BAK, and RWLK.
Jan 27, 2022 03:05 pm ET
Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA
RED BANK, N.J., Jan. 27, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced its intent to resubmit the teplizumab Biologics License Application (BLA) for the delay of clinical type 1 diabetes in at-risk individuals following its Type B pre-BLA resubmission meeting with the U.S. Food and Drug Administration (FDA).
Jan 20, 2022 03:05 pm ET
Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE)
RED BANK, N.J., Jan. 20, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the Phase 2a PREVAIL-2 study (PRV-3279 EVAluation In Lupus- Phase 2). PRV-3279 is an investigational humanized bispecific DART molecule targeting the B-cell surface proteins CD32B and CD79B, which has the potential to intercept the pathophysiology of systemic lupus erythematosus (SLE) and other B cell-mediated autoimmune diseases, as well as to prevent the immunogenicity of biotherape
Jan 07, 2022 06:30 am ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., Jan. 7, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to Randy Anderson, Senior Vice President of Biometrics to purchase an aggregate of 130,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to Mr. Anderson entering into employment with the Company pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation c
Jan 06, 2022 06:30 am ET
Provention Bio to Present at the Virtual H.C. Wainwright BioConnect Conference
RED BANK, N.J., Jan. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will present at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.
Dec 20, 2021 06:34 am ET
Provention Bio Announces Leadership Team Expansion
RED BANK, N.J., Dec. 20, 2021 /PRNewswire/ -- December 20, 2021— Provention Bio, Inc. (NASDAQ: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has appointed Christina Yi as Chief Operations Officer, responsible for manufacturing, supply chain and human resources, and Benedict Osorio as Chief Quality Officer, responsible for all aspects of quality. These new leadership appointments reinforce Proventions' commitment to quality manufacturing and supply chain excellence and investment in human
Dec 02, 2021 06:30 am ET
Provention Bio Announces the Grant of Inducement Awards
RED BANK, N.J., Dec. 2, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to two new employees to purchase an aggregate of 550,000 shares of the Company's common stock. 375,000 stock options were granted to Thierry Chauche, the Company's Chief Financial Officer, and 175,000 stock options were granted to Jan Hillson, the Company's Senior Vice President of Clinical Development. The stock options were granted without stockh
Nov 22, 2021 07:30 am ET
Thinking about buying stock in Astra Space, PainReform, Vonage, Affimed NV, or Provention Bio?
NEW YORK, Nov. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ASTR, PRFX, VG, AFMD, and PRVB.
Nov 22, 2021 06:30 am ET
Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway
RED BANK, N.J., Nov. 22, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update on its ongoing efforts to address U.S. Food and Drug Administration (FDA) considerations cited in the Complete Response Letter (CRL) issued to the Company by the FDA on July 2, 2021, pertaining to comparability between the Company's planned teplizumab commercial product and clinical drug product used in historical trials of teplizumab.
Nov 17, 2021 06:30 am ET
Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development
RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D., as Senior Vice President of Clinical Development. Dr. Hillson bolsters the Company's clinical development leadership group with significant experience in all phases of clinical development across various autoimmune disorders, including systemic lupus erythematosus, which is the lead target indication for PRV-3279, a DART® (bispecific antibody-based molecule) target
Nov 09, 2021 07:00 am ET
Provention Bio Puts Type 1 Diabetes to the Test with Pledge Campaign for Diabetes Awareness Month
RED BANK, N.J., Nov. 9, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it's putting type 1 diabetes (T1D) to the test during Diabetes Awareness Month this November. The company is calling on the T1D community to take the #Type1TestedPledge to spread awareness about risk factors and the importance of screening people with a family history of T1D for early-stage, pre-symptomatic disease. Screening may reduce the risk of serious complications and life-threatening events such
Nov 05, 2021 04:30 pm ET
Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development
RED BANK, N.J., Nov. 5, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development. Dr. Sanjuan further strengthens the Company's internal expertise in the core areas of immunomodulatory therapy, translational medicine and autoimmune disease.
Nov 04, 2021 07:05 am ET
Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer
RED BANK, N.J., Nov. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that Thierry Chauche will become Chief Financial Officer effective December 1, 2021 and Andrew Drechsler will be retiring, following a career of nearly 30 years in the financial and life sciences industry, most notably, the past four years at Provention Bio. Mr. Drechsler will continue to serve as a special advisor to the CEO and consultant through the middle of 2022.
Nov 04, 2021 07:00 am ET
Provention Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
RED BANK, N.J., Nov. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.
Oct 28, 2021 07:30 am ET
Provention Bio to Report Third Quarter 2021 Financial Results on November 4, 2021
RED BANK, N.J., Oct. 28, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its third quarter 2021 financial results on Thursday, November 4, 2021, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a corporate update.
Oct 26, 2021 07:30 am ET
Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
RED BANK, N.J., Oct. 26, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced positive interim results from PROVENT (PROtocol for coxsackievirus VaccinE in healthy voluNTeers), a first-in-human study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate targeting all five key CVB strains associated with type 1 diabetes (T1D) autoimmunity. Provention is developing PRV-101 for the prevention of acute CVB infection and the potential delay or prevention of T
Oct 21, 2021 09:32 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Provention Bio, Danimer Scientific, AcelRX, and Piedmont Lithium on Behalf of Long-Term Stockholders and Encourages Investors t
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Provention Bio, Inc. (NASDAQ: PRVB), Danimer Scientific, Inc. (NYSE: DNMR), AcelRX Pharmaceuticals, Inc. (NASDAQ:...
Sep 23, 2021 07:30 am ET
Provention Bio to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021
RED BANK, N.J., Sept. 23, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021 on Wednesday, September 29, 2021 at 3:20 pm E.T.
Sep 16, 2021 07:30 am ET
Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
RED BANK, N.J., Sept. 16, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Wednesday, September 22, 2021 at 9:05 am E.T.
Sep 13, 2021 07:30 am ET
Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission
RED BANK, N.J., Sept. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update on the status and timing of its ongoing efforts to address FDA considerations cited in the Complete Response Letter (CRL) issued to the Company by the FDA on July 2, 2021.
Aug 09, 2021 08:37 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Provention Bio and Ontrak on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Provention Bio, Inc. (NASDAQ: PRVB), and Ontrak, Inc. (NASDAQ: OTRK) on behalf of long-term stockholders. More...
Aug 06, 2021 02:04 pm ET
Lifshitz Law Firm, P.C. Announces Investigations of ContextLogic, Inc. (NasdaqGS: WISH), Provention Bio, Inc. (NasdaqGS: PRVB), Ubiquiti Inc. (NYSE: UI), and Virgin Galactic holdings, Inc. (NYSE: SPCE
ContextLogic, Inc. (NasdaqGS: WISH) Lifshitz Law Firm, P.C. announces that a class action complaint was filed against WISH alleging that in the Registration Statement and Prospectus used to conduct the IPO and throughout the Class Period, WISH...
Aug 05, 2021 07:00 am ET
Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
RED BANK, N.J., Aug. 5, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.
Jul 29, 2021 07:00 am ET
Provention Bio to Report Second Quarter 2021 Financial Results on August 5, 2021
RED BANK, N.J., July 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2021 financial results on Thursday, August 5, 2021, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a corporate update.
Jul 19, 2021 03:00 pm ET
Last Few Hours to Actively Participate in Provention Bio, Inc. (PRVB) Class Action - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers, on behalf of...
Jul 19, 2021 10:40 am ET
DEADLINE ALERT for UI, PRVB, and WPG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 19, 2021 10:00 am ET
PRVB Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: July 20, 2021
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Jul 18, 2021 09:30 am ET
FINAL DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – PRVB
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”), of the important July 20, 2021 lead...
Jul 18, 2021 09:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company")(NASDAQ: PRVB) and certain of its officers.   The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages cau
Jul 16, 2021 11:25 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
The Law Offices of Frank R. Cruz reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ:
Jul 15, 2021 06:05 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline – PRVB
Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. (“Provention” or the “Company”)(NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District...
Jul 15, 2021 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
LOS ANGELES, July 15, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the "Class Period").
Jul 15, 2021 11:00 am ET
DEADLINE ALERT for PRVB, WPG, SPCE, OCGN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 14, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Provention Bio, Washington Prime, Virgin Galactic, and RLX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Provention Bio, Inc. (NASDAQ: PRVB), Washington Prime Group, Inc. (NYSE: WPG),...
Jul 12, 2021 04:51 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action – PRVB
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”), of the important July 20, 2021 lead...
Jul 12, 2021 11:30 am ET
DEADLINE ALERT for WISH, UI, PRVB, and WPG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 12, 2021 07:00 am ET
Teplizumab Awarded Innovation Passport in the United Kingdom (UK) for the Delay of Onset of Clinical Type 1 Diabetes in At-risk Individuals
RED BANK, N.J., July 12, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that teplizumab, an anti-CD3 monoclonal antibody (mAb), was awarded an Innovation Passport for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. Teplizumab is one of the first investigational medicines to receive this designation under the United Kingdom's (UK) Innovative Licensing and Access Pathway (ILAP) launched by The Medicines and Healthcare products Regulatory Agency (MHRA) in
Jul 10, 2021 06:46 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
NEW YORK, July 10, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company")(NASDAQ: PRVB) and certain of its officers.  The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caus
Jul 09, 2021 02:00 pm ET
DEADLINE ALERT for PRVB, WPG, SPCE, OCGN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 08, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Provention Bio, Inc. ("Provention" or...
Jul 08, 2021 10:00 am ET
PRVB, WPG & SPCE Deadline Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jul 07, 2021 11:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Provention Bio, Washington Prime, Virgin Galactic, and RLX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Provention Bio, Inc. (NASDAQ: PRVB), Washington Prime Group, Inc. (NYSE: WPG),...
Jul 07, 2021 08:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline – PRVB
Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. (“Provention” or the “Company”)(NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District...
Jul 07, 2021 11:30 am ET
DEADLINE ALERT for WISH, UI, PRVB, and WPG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 06, 2021 04:30 pm ET
Portnoy Law: Lawsuit Filed On Behalf of Provention Bio, Inc. Investors
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) investors that acquired securities between November 2, 2020 and April 8, 2021....
Jul 06, 2021 03:20 pm ET
(PRVB) Deadline Alert: Investors Interested in Being a Lead Plaintiff in Securities Fraud Class Action Lawsuit Against Provention Bio – Contact Johnson Fistel
Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Provention Bio, Inc. (NASDAQ: PRVB) ("Provention" or the "Company"). The class action is on behalf of shareholders who...
Jul 06, 2021 10:30 am ET
Thinking about buying stock in Exela Technologies, Larimar Therapeutics, Marin Software, Provention Bio, or BioLineRx?
NEW YORK, July 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XELA, LRMR, MRIN, PRVB, and BLRX.
Jul 06, 2021 09:53 am ET
(PRVB) Deadline Alert: Investors Interested in Being a Lead Plaintiff in Securities Fraud Class Action Lawsuit Against Provention Bio - Contact Johnson Fistel
SAN DIEGO, July 6, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Provention Bio, Inc. (NASDAQ: PRVB) ("Provention" or the "Company"). The class action is on behalf of shareholders who purchased Provention between November 2, 2020 - April 8, 2021 both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff in this class action, you must move the Court no later than July 20, 2021.
Jul 06, 2021 07:00 am ET
Provention Bio Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals
RED BANK, N.J., July 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.
Jul 05, 2021 10:08 am ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Provention Bio, Inc. Investors With Losses to Secure Counsel Before Important July 20 Deadline in Securities Class Action – PRVB
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”), of the important July 20, 2021 lead...
Jul 02, 2021 05:03 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB
NEW YORK, July 2, 2021 /PRNewswire/ -- WHY: New York, N.Y., July 2, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline.
Jul 02, 2021 08:30 am ET
Thinking about buying stock in Provention Bio, Virgin Galactic, Staffing 360 Solutions, Atossa Therapeutics, or Marin Software?
NEW YORK, July 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRVB, SPCE, STAF, ATOS, and MRIN.
Jul 01, 2021 09:17 pm ET
Shareholder Alert: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
NEW YORK, July 01, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers.   The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages ca
Jul 01, 2021 10:48 am ET
DEADLINE ALERT for PRVB, WPG, SPCE, OCGN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 30, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Provention Bio, Washington Prime, Virgin Galactic, and RLX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Provention Bio, Inc. (NASDAQ: PRVB), Washington Prime Group, Inc. (NYSE: WPG),...
Jun 30, 2021 12:05 pm ET
DEADLINE ALERT for WISH, UI, PRVB, and WPG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 29, 2021 12:30 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Provention Bio, Inc. ("Provention" or...
Jun 29, 2021 10:00 am ET
PRVB, WPG & SPCE Investor Alert: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 28, 2021 04:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline – PRVB
Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. (“Provention” or the “Company”)(NASDAQ: PRVB) and certain of its officers.   The class action, filed in the United States District Court for the...
Jun 24, 2021 12:30 pm ET
DEADLINE ALERT for PRVB, WPG, SPCE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 23, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Provention Bio, Washington Prime, Virgin Galactic, and RLX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Provention Bio, Inc. (NASDAQ: PRVB), Washington Prime Group, Inc. (NYSE: WPG),...
Jun 23, 2021 05:32 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors With Losses Over $100K to Secure Counsel Before Important July 20 Deadline in Securities Class Action – PRVB
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”), of the important July 20, 2021 lead...
Jun 23, 2021 12:30 pm ET
DEADLINE ALERT for WISH, UI, PRVB, and WPG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 23, 2021 11:00 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors
LOS ANGELES, June 23, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"). Provention investors have until July 20, 2021 to file a lead plaintiff motion.
Jun 22, 2021 06:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
NEW YORK, June 22, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers.  The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages cau
Jun 22, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Provention Bio, Inc. ("Provention" or...
Jun 21, 2021 11:30 am ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
BENSALEM, Pa. ­­, June 21, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the "Class Period").
Jun 20, 2021 12:57 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline – PRVB
Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. (“Provention” or the “Company”)(NASDAQ: PRVB) and certain of its officers.   The class action, filed in the United States District Court for the...
Jun 19, 2021 04:15 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PRVB
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”), of the important July 20, 2021 lead...
Jun 18, 2021 11:15 am ET
DEADLINE ALERT for WISH, UI, PRVB, and WPG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 17, 2021 11:45 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Provention Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PRVB
NEW YORK, June 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline.
Jun 17, 2021 11:00 am ET
DEADLINE ALERT for FUV, PRVB, WPG, SPCE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 17, 2021 10:00 am ET
PRVB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers, on behalf of...
Jun 16, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Provention Bio, Washington Prime, Virgin Galactic, and RLX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Provention Bio, Inc. (NASDAQ: PRVB), Washington Prime Group, Inc. (NYSE: WPG),...
Jun 16, 2021 04:56 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
NEW YORK, June 16, 2021 /PRNewswire/ --  Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company")(NASDAQ: PRVB) and certain of its officers.  The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages cau
Jun 15, 2021 11:30 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
LOS ANGELES, June 15, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the "Class Period").
Jun 14, 2021 07:56 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline – PRVB
Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. (“Provention” or the “Company”)(NASDAQ: PRVB) and certain of its officers.   The class action, filed in the United States District Court for the...
Jun 11, 2021 05:52 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action – PRVB
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”), of the important July 20, 2021 lead...
Jun 11, 2021 11:15 am ET
DEADLINE ALERT for WISH, UI, PRVB, and WPG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 11, 2021 03:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
NEW YORK, June 11, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caus
Jun 11, 2021 01:10 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
NEW YORK, June 11, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caus
Jun 10, 2021 12:30 pm ET
DEADLINE ALERT for CAN, FKWL, INTZ, PRVB: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 10, 2021 10:00 am ET
PRVB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers, on behalf of...
Jun 09, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Provention Bio, Washington Prime, and Virgin Galactic and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Provention Bio, Inc. (NASDAQ: PRVB), Washington Prime Group, Inc. (NYSE: WPG),...
Jun 07, 2021 09:00 am ET
Robbins Geller Rudman & Dowd LLP Announces Upcoming Lead Plaintiff Deadline in the Provention Bio, Inc. Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers of Provention Bio, Inc. (NASDAQ:PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”) have until July 20, 2021 to seek appointment as lead plaintiff in the Provention Bio class action
Jun 04, 2021 07:15 pm ET
PRVB BREAKING ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline – PRVB
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”), of the important July 20, 2021 lead...
Jun 04, 2021 12:30 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ:
Jun 04, 2021 11:00 am ET
DEADLINE ALERT for WISH, UI, PRVB, and WPG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 02, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Provention Bio, Washington Prime, and Virgin Galactic and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Provention Bio, Inc. (NASDAQ: PRVB), Washington Prime Group, Inc. (NYSE: WPG),...
Jun 02, 2021 11:00 am ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
Law Offices of Howard G. Smith reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”).
Jun 02, 2021 11:00 am ET
PRVB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Provention Bio, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Jun 01, 2021 12:42 pm ET
SHAREHOLDER ALERT: Robbins LLP Reminds Investors that Provention Bio, Inc. (PRVB) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of Provention Bio, Inc. (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, against the Company and certain of its officers for remedies under the Securities Exchange Act of 1934. Provent
May 30, 2021 03:45 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important July 20 Deadline – PRVB
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 20, 2021.
May 28, 2021 03:35 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors With Losses Over $100K to Secure Counsel Before Important July 20 Deadline – PRVB
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the...
May 28, 2021 01:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ:
May 27, 2021 10:12 pm ET
Portnoy Law: Lawsuit Filed On Behalf of Provention Bio, Inc. Investors
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) investors that acquired securities between November 2, 2020 and April 8, 2021....
May 27, 2021 01:00 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Provention Bio, Inc. (PRVB) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ:
May 27, 2021 01:00 pm ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ:
May 27, 2021 12:42 pm ET
SHAREHOLDER ALERT: Robbins LLP Announces that Provention Bio, Inc. (PRVB) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of Provention Bio, Inc. (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, against the Company and certain of its officers for remedies under the Securities Exchange Act of 1934. Provention is a clinic
May 27, 2021 11:00 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”). Provention investors have until July 20, 2021 to file a lead
May 27, 2021 10:00 am ET
PRVB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Provention Bio, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers, on behalf of...
May 26, 2021 12:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Provention Bio, Inc. (PRVB) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ:
May 26, 2021 08:57 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. (“Provention” or “the Company”) (NASDAQ:
May 25, 2021 05:13 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Provention Bio, Inc. (PRVB)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Provention Bio, Inc. (“Provention”) (NASDAQ: PRVB) in the United States District Court for the District of New Jersey on behalf of those who purchased or...
May 25, 2021 04:58 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Provention Bio, Inc. (PRVB) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) investors concerning the Company’s possible violations of federal securities laws.
May 25, 2021 02:08 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. (“Provention” or “the Company”) (NASDAQ:
May 25, 2021 11:38 am ET
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline – PRVB
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 20, 2021.
May 24, 2021 11:48 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline – PRVB
Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. (“Provention” or the “Company”)(NASDAQ: PRVB) and certain of its officers.   The class action, filed in the United States District Court for the...
May 24, 2021 11:00 pm ET
PROVENTION ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Provention Bio, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of investors that purchased Provention Bio, Inc. (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, both dates inclusive (the “Class Period”). Investors have until July 20, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
May 21, 2021 10:40 pm ET
Notice of Lead Plaintiff Deadline for Shareholders in the Provention Bio, Inc. Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the District of New Jersey on behalf of purchasers of Provention Bio, Inc. (NASDAQ:PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”). The case is captioned
Apr 24, 2021 10:56 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Provention Bio, Inc. - PRVB
Pomerantz LLP is investigating claims on behalf of investors of Provention Bio, Inc. (“Provention” or the “Company”) (NASDAQ: PRVB).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Feb 25, 2021 06:00 am ET
Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
RED BANK, N.J., Feb. 25, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the fourth quarter and full year ended December 31, 2020.
Feb 18, 2021 06:30 am ET
Provention Bio to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
RED BANK, N.J., Feb. 18, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth quarter and full year 2020 financial results on February 25, 2021 before the opening of the U.S. financial markets.  Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a corporate update.
Feb 17, 2021 03:00 pm ET
Provention Bio and Huadong Announce Strategic Collaboration to Develop and Commercialize PRV-3279 in Greater China
RED BANK, N.J., Feb. 17, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd., today announced that the companies have entered into a strategic collaboration to develop and commercialize PRV-3279, a DART® (bispecific antibody-based molecule) targeting the B cell surface proteins CD32B and CD79B, in Greater China (mainland China, Hong Kong, Macau and Taiwan).  Provention Bio will reta
Jan 28, 2021 06:30 am ET
Provention Bio Announces Key Findings from Pre-clinical Proof-of-concept Study for PRV-3279 for the Prevention of Immunogenicity of Gene Therapy
RED BANK, N.J., Jan. 28, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported results from a pre-clinical proof-of-concept study for PRV-3279, a DART® (bispecific antibody-based molecule) targeting the B cell surface proteins CD32B and CD79B, conducted in a murine model of gene therapy for Pompe disease. A PRV-3279 mouse surrogate was tested in mice transgenic for human CD32B, which received gene therapy with an adeno-associated virus (AAV) vector AAV9 encoding for the enzyme ac
Jan 13, 2021 06:03 pm ET
Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock
RED BANK, N.J., Jan. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $16.00 per share. Gross proceeds to Provention Bio from the offering are expected to be $100 million, before deducting underwriting discounts and commissions and other offering expenses payable by Provention Bio. In addition, Provention Bio has granted the un
Jan 12, 2021 03:26 pm ET
Provention Bio Announces Proposed Public Offering of Common Stock
RED BANK, N.J., Jan. 12, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares to be sold in the offering are to be sold by Provention Bio. In connection with the offering, Provention Bio intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. The offering is subject to market and other conditions, an
Jan 06, 2021 03:05 pm ET
Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference
RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the H.C. Wainwright BioConnect 2021 Conference, being held virtually January 11-14, 2021.
Jan 04, 2021 06:00 am ET
Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
RED BANK, N.J., Jan. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Biologics License Application (BLA) for teplizumab for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals has been filed by the U.S. Food and Drug Administration (FDA). The FDA also granted Provention's request for Priority Review and assigned a user fee goal date of July 2, 2021, under the Prescription Drug User-Fee Act (PDUFA).
Dec 21, 2020 06:30 am ET
Provention Bio Announces Addition to NASDAQ Biotechnology Index
RED BANK, N.J., Dec. 21, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open today.
Dec 15, 2020 06:30 am ET
Provention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
RED BANK, N.J., Dec. 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of PROVENT (PROtocol for coxsackievirus VaccinE in healthy voluNTeers), a first-in-human study of its polyvalent inactivated coxsackievirus B (CVB) vaccine candidate, PRV-101. Provention is developing PRV-101 for the prevention of acute CVB infection and the potential delay or prevention of type 1 diabetes (T1D) and celiac disease.
Dec 08, 2020 07:55 am ET
JDRF Launches First Mass Screening Program for Early-Stage Type 1 Diabetes (T1D) Detection
NEW YORK and RED BANK, N.J., Dec. 8, 2020 /PRNewswire/ -- On the heels of National Diabetes Awareness Month, JDRF, the leading global funder of type 1 diabetes (T1D) research, has launched a groundbreaking screening initiative for T1D: T1Detect. Designed to make early detection of T1D easier and more accessible to a broad population, financial assistance is available for the cost of the screening. The initiative is supported by founding sponsor Provention Bio (Nasdaq: PRVB), a biopharmaceutical company focused on intercepting and preventing autoimmune disease.
Nov 11, 2020 06:30 am ET
Provention Bio to Present at the Stifel Virtual Healthcare Conference
RED BANK, N.J., Nov. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that management will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020, at 8:00 am E.T.
Nov 05, 2020 06:00 am ET
Provention Bio Reports Third Quarter 2020 Financial Results and Provides Business Update
RED BANK, N.J., Nov. 5, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today reported financial results for the third quarter ended September 30, 2020, and provided a business update.
Nov 02, 2020 06:30 am ET
Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
RED BANK, N.J., Nov. 2, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for teplizumab for the delay or prevention of clinical type one diabetes (T1D) in at-risk individuals with the submission of the chemistry, manufacturing and controls (CMC) and administrative information modules.
Oct 29, 2020 07:30 am ET
Provention Bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020
RED BANK, N.J., Oct. 29, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020.
Aug 06, 2020 07:00 am ET
Provention Bio Reports Second Quarter 2020 Financial Results and Provides Business Update
OLDWICK, N.J., Aug. 6, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the second quarter ended June 30, 2020 and provided a business update.
Aug 03, 2020 04:05 pm ET
Provention Bio Appoints Heidy Abreu King-Jones as Chief Legal Officer
OLDWICK, N.J., Aug. 3, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Heidy Abreu King-Jones to the newly created role of Chief Legal Officer. Ms. King-Jones brings nearly 12 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. 
Jul 30, 2020 07:00 am ET
Provention Bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020
OLDWICK, N.J., July 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020.
Jun 30, 2020 04:30 pm ET
Provention Bio Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of the Stockholders
OLDWICK, N.J., June 30, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today a change in the format of its 2020 Annual Meeting of Stockholders (the "Annual Meeting") from in-person to a virtual-only meeting format due to the continuing public health impact of COVID-19 and to support the health and safety of the Company's stockholders and attendees. As previously announced, the Annual Meeting will be held on Wednesday, July 15 at 9:00 a.m. Eastern Time ("ET").
Jun 29, 2020 07:00 am ET
Provention Bio Announces Inclusion in the Russell 3000 Index and Russell 2000 Index
OLDWICK, N.J., June 29, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has been added to the broad-market Russell 3000® Index and the small-cap Russell 2000® Index as part of the Russell US Indexes annual reconstitution.
Jun 22, 2020 04:01 pm ET
Provention Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
OLDWICK, N.J., June 22, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of the previously announced public offering of 7,590,000 shares of common stock, including 990,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $14.50 per share. The gross proceeds to Provention Bio from the offering, before deducting underwriting discounts and commissions and other expense payable by Pro
Jun 17, 2020 10:16 pm ET
Provention Bio Announces Pricing of $95.7 Million Public Offering of Common Stock
OLDWICK, N.J., June 17, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $14.50 per share. Gross proceeds to Provention Bio from the offering are expected to be $95.7 million, before deducting underwriting discounts and commissions and other offering expenses payable by Provention Bio. In addition, Provention Bio has granted the underwr
Jun 16, 2020 04:01 pm ET
Provention Bio Announces Proposed Public Offering of Common Stock
OLDWICK, N.J., June 16, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has commenced an underwritten public offering of 5,500,000 shares of its common stock. All of the shares to be sold in the offering are to be sold by Provention Bio. In connection with the offering, Provention Bio intends to grant the underwriters a 30-day option to purchase up to an additional 825,000 shares of its common stock. The offering is subject to market and other conditions, and ther
Jun 15, 2020 12:02 pm ET
Provention Bio's Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients
OLDWICK, N.J., June 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced extended follow-up data showing a single 14-day course of teplizumab (PRV-031) significantly delayed the onset of insulin-dependent type 1 diabetes (T1D) in presymptomatic patients by a median of approximately three years compared to placebo. These new data from the pivotal "At-Risk" TN-10 Study add one year to the two-year median delay that was previously reported in the New England Journal of Medicine
May 28, 2020 07:00 am ET
Provention Bio to Present at the Jefferies Virtual Healthcare Conference
OLDWICK, N.J., May 28, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020, at 8:30 am E.T. 
May 20, 2020 07:00 am ET
Provention Bio Announces Changes to its Board of Directors
OLDWICK, N.J., May 20, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced two changes to its board of directors.
May 18, 2020 07:00 am ET
Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine
OLDWICK, N.J. and TAMPERE, Finland, May 18, 2020 /PRNewswire/ --  Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease and its licensor, Vactech Oy (Vactech), a Finnish biotechnology company focused on development of vaccines for Type 1 Diabetes (T1D) and other immune mediated diseases, today announced the publication of results demonstrating that a preclinical prototype of Provention's polyvalent coxsackievirus B (CVB) vaccine, PRV-101, is well-tolerated, immunogenic and highly protective in relevant
May 07, 2020 04:05 pm ET
Provention Bio Reports First Quarter 2020 Financial Results and Provides Business Update
OLDWICK, N.J., May 7, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2020.
Apr 30, 2020 07:00 am ET
Provention Bio to Report First Quarter 2020 Financial Results and Host Conference Call on Thursday, May 7, 2020
OLDWICK, N.J., April 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its first quarter 2020 financial results on Thursday, May 7, 2020.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.